title: Increased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cells.
abstract: Vascular calcification is recognized as an independent predictor of cardiovascular mortality, particularly in subjects with chronic kidney disease. However, the pathways by which dysregulation of lipid and mineral metabolism simultaneously occur in this particular population remain unclear. We have shown that activation of the farnesoid X receptor (FXR) blocks mineralization of bovine calcifying vascular cells (CVCs) and in ApoE knock-out mice with 5/6 nephrectomy. In contrast to FXR, this study showed that liver X receptor (LXR) activation by LXR agonists and adenovirus-mediated LXR overexpression by VP16-LXRα and VP16-LXRβ accelerated mineralization of CVCs. Conversely, LXR inhibition by dominant negative (DN) forms of LXRα and LXRβ reduced calcium content in CVCs. The regulation of mineralization by FXR and LXR agonists was highly correlated with changes in lipid accumulation, fatty acid synthesis, and the expression of sterol regulatory element binding protein-1 (SREBP-1). The rate of lipogenesis in CVCs through the SREBP-1c dependent pathway was reduced by FXR activation, but increased by LXR activation. SREBP-1c overexpression augmented mineralization in CVCs, whereas SREBP-1c DN inhibited alkaline phosphatase activity and mineralization induced by LXR agonists. LXR and SREBP-1c activations increased, whereas FXR activation decreased, saturated and monounsaturated fatty acids derived from lipogenesis. In addition, we found that stearate markedly promoted mineralization of CVCs as compared with other fatty acids. Furthermore, inhibition of either acetyl-CoA carboxylase or acyl-CoA synthetase reduced mineralization of CVCs, whereas inhibition of stearoyl-CoA desaturase induced mineralization. Therefore, a stearate metabolite derived from lipogenesis might be a risk factor for the development of vascular calcification.
authors: Division of Renal Diseases and Hypertension, Department of Medicine, Denver VA Medical Center and University of Colorado, Denver, Aurora, Colorado 80045, USA.
authors: Tabitha C
authors: TC
authors: Ting
authors: Shinobu
authors: S
authors: Miyazaki-Anzai
authors: Masashi
authors: M
authors: Masuda
authors: Moshe
authors: M
authors: Levi
authors: Linda L
authors: LL
authors: Demer
authors: Yin
authors: Y
authors: Tintut
authors: Makoto
authors: M
authors: Miyazaki
references: J Lipid Res. 2009 Feb;50(2):312-26
references: 18812595
references: J Biol Chem. 2003 Sep 26;278(39):37041-51
references: 12865424
references: J Biol Chem. 2001 Nov 30;276(48):45358-66
references: 11567032
references: Mol Endocrinol. 2003 Jun;17(6):985-93
references: 12690094
references: Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9558-61
references: 9689119
references: Endocr Rev. 2002 Aug;23(4):443-63
references: 12202460
references: Curr Opin Pharmacol. 2003 Apr;3(2):192-7
references: 12681243
references: J Biol Chem. 2002 Sep 13;277(37):34182-90
references: 12097330
references: J Biol Chem. 2004 Apr 23;279(17):16971-9
references: 14966134
references: Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3077-82
references: 12629214
references: J Biol Chem. 2001 May 4;276(18):14890-5
references: 11278654
references: Proc Natl Acad Sci U S A. 2002 May 28;99(11):7604-9
references: 12032330
references: J Biol Chem. 2007 Jan 26;282(4):2483-93
references: 17127673
references: Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12097-102
references: 11035776
references: Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11245-50
references: 15266058
references: Nat Med. 2009 Dec;15(12):1383-91
references: 19966778
references: J Lipid Res. 2002 Jun;43(6):911-20
references: 12032166
references: Cell. 2006 Aug 25;126(4):789-99
references: 16923397
references: J Biol Chem. 2008 Mar 21;283(12):7936-48
references: 18162472
references: Endocrinology. 2010 Jul;151(7):3061-73
references: 20444946
references: Mol Cell Biol. 2006 Sep;26(18):6786-98
references: 16943421
references: Circ Res. 2005 Apr 15;96(7):717-22
references: 15831823
references: J Biol Chem. 2007 Jan 5;282(1):743-51
references: 17107947
references: J Am Soc Nephrol. 2009 Jul;20(7):1453-64
references: 19478096
references: Lipids. 2005 Dec;40(12):1187-91
references: 16477801
references: Physiol Rev. 2009 Jan;89(1):147-91
references: 19126757
references: Circulation. 2002 Aug 27;106(9):1077-82
references: 12196332
references: J Lipid Res. 2006 Nov;47(11):2451-61
references: 16931873
references: J Biol Chem. 2001 May 18;276(20):16683-9
references: 11278967
references: J Biol Chem. 2002 Mar 29;277(13):11019-25
references: 11790787
references: J Biol Chem. 1998 Dec 4;273(49):32487-90
references: 9829981
references: J Clin Invest. 2004 May;113(10):1408-18
references: 15146238
references: Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3668-73
references: 14990788
references: Genes Dev. 2000 Nov 15;14(22):2819-30
references: 11090130
references: N Engl J Med. 1998 Dec 31;339(27):1972-8
references: 9869668
references: J Lipid Res. 2003 Mar;44(3):479-86
references: 12562875
references: J Bone Miner Metab. 2006;24(2):176-81
references: 16502129
references: J Biol Chem. 2001 Feb 9;276(6):4365-72
references: 11085986
references: Circ Res. 2010 Jun 25;106(12):1807-17
references: 20431060
references: Genes Dev. 1996 May 1;10(9):1096-107
references: 8654925
references: Prostaglandins Leukot Essent Fatty Acids. 2003 Feb;68(2):113-21
references: 12538075
references: Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E275-81
references: 16492686
references: J Clin Invest. 1997 Jul 15;100(2):290-5
references: 9218505
references: FEBS Lett. 2008 Jan 9;582(1):10-8
references: 18023284
references: Cell Metab. 2007 Dec;6(6):484-96
references: 18054317
references: Am Heart J. 2010 Nov;160(5):785-794.e10
references: 21095263
references: FEBS Lett. 2009 Apr 17;583(8):1344-8
references: 19327357
references: Genes Dev. 2000 Nov 15;14(22):2831-8
references: 11090131